Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21033473 | 0.86 | KDM4E (0.67) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL16598434 | 0.84 | KDM4E (0.49) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL31035800 | 0.83 | KDM4E (0.64) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL2517089 | 0.83 | KDM4E (0.64) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL974963 | 0.83 | KDM4E (0.64) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL5269616 | 0.82 | KDM4E (0.58) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL6619045 | 0.81 | HPGD (0.47) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL2067013 | 0.81 | KDM4E (0.61) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL14417633 | 0.81 | KDM4E (0.61) | KDM4ERAB9ANPC1RXFP1KMT2A | |
| SCHEMBL12891189 | 0.81 | KDM4E (0.61) | KDM4ERAB9ANPC1RXFP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022131-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-22 | — | — | US | disclosed |
| US-12473302-B2 | 4-phenylpiperidines, their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-11-18 | — | — | US | disclosed |
| US-12473303-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use | Carrick Therapeutics Limited (IE) | 2025-11-18 | — | — | US | disclosed |
| EP-4612151-A1 | PREPARATION OF IMIDAZOPYRIDINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | Merck Sharp & Dohme LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-114929708-B | 4- [ [ (7-Aminopyrazolo [1,5-a ] pyrimidin-5-yl) amino ] methyl ] piperidin-3-ol compounds and their therapeutic uses | 卡里克治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240287092-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2024097573-A1 | PREPARATION OF IMIDAZOPYRIDINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20240124469-A1 | PIM KINASE INHIBITOR | HANGZHOU BIOSUN PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| CN-111542523-B | Heterocyclic compounds as PRMT5 inhibitors | 朱比连特埃皮斯科瑞有限责任公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-3704120-B1 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | JUBILANT EPISCRIBE LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20050032650-A1 | Fused heterocyclic sulfonylurea compound herbicide containing the same and method of controlling weed with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-0979231-B1 | CONDENSED PYRIDAZINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| EP-1466527-A1 | FUSED HETEROCYCLIC SULFONYLUREA COMPOUND, HERBICIDE CONTAINING THE SAME, AND METHOD OF CONTROLLING WEED WITH THE SAME | Sumitomo Chemical Takeda Agro Company, Limited (JP) | 2004-10-13 | — | — | EP | disclosed |
| EP-1123936-B1 | FUSED PYRIDAZINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-6627630-B1 | Preventing or treating allergic skin diseases such as contact dermatitis, pruritus, dried dermatitis, acute urticaria prurigo and antiallergins | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-30 | — | — | US | disclosed |
| EP-1243271-A1 | NASAL DROPS CONTAINING FUSED PYRIDAZINE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1123936-A1 | FUSED PYRIDAZINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2001-08-16 | — | — | EP | disclosed |
| US-6248740-B1 | FOR SUPPRESSION OF HISTAMINE OR EOSINOPHIL CHEMOTAXIS TO TREAT ASTHMA; ANTIALLERGENIC | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| EP-0979231-A1 | CONDENSED PYRIDAZINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998049167-A1 | CONDENSED PYRIDAZINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287092-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | HTR3C, HRH4, DRD3 | KDM4E 1319/4885RAB9A 1612/4885NPC1 3005/4885 |
| US-12473302-B2 | 4-phenylpiperidines, their preparation and use | HTR3C, HRH4, DRD3 | KDM4E 1319/4885RAB9A 1612/4885NPC1 3005/4885 |
| US-20240124469-A1 | PIM KINASE INHIBITOR | PIM1, PIM2, PIM3 | KDM4E 609/4885RAB9A 2637/4885NPC1 1186/4885 |
| US-12473303-B2 | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino methyl]piperidin-3-ol compounds and their therapeutic use | CDK3, CDK1, CDK2 | KDM4E 1437/4885RAB9A 2959/4885NPC1 3932/4885 |
| US-20050032650-A1 | Fused heterocyclic sulfonylurea compound herbicide containing the same and method of controlling weed with the same | NOTUM, WEE1, DDT | KDM4E 683/4885RAB9A 1361/4885NPC1 4756/4885 |
| US-20260022131-A1 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | CLN6, NR2E3, CBR3 | KDM4E 3025/4885RAB9A 1209/4885NPC1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.